Quantcast
Channel: MassBio Upcoming Events
Viewing all 2057 articles
Browse latest View live

Metabolic Disease Drug Development

0
0

Expanding epidemic. Unmet medical need. Enormous market potential.

Where will innovation come from in the metabolic drug pipeline? What clinical strategies will satisfy regulators?

Answering these questions holds the key to dominating the enormous and expanding cardiometabolic market.

Continuing unmet medical need, bottlenecks in the pipeline and a harsh regulatory climate remain strong drivers for enhancing your metabolic drug development strategy.

By giving you unparalleled access to the minds behind the most promising drugs in development, Metabolic Disease Drug Development will provide the perfect platform to address these concerns and direct your preclinical and clinical development strategy.

Metabolic Disease Drug Development guarantees strong representation and candid discussion from senior level figures at Pfizer, Merck, BMS and the most innovative biotechs in the field. It will provide valuable insight into identifying and validating new metabolic drug targets, streamlining clinical strategy and speeding the passage of your drugs to market.

MassBio members are eligible for a 10% discount off the registration fee. Simply quote ‘MASSBIO’ when registering:  http://metabolicdisease-drugdev.com/register

 

www.metabolicdisease-drugdev.com


The Great Pumpkin Glow: Kendall Square Corporate Pumpkin Carving Challenge

0
0

The Boys & Girls Clubs of Middlesex County is celebrating Halloween with a Pumpkin Carving Corporate Challenge. Join your Kendall Square neighbors, employees and friends for music, light refreshments and the Great Pumpkin Glow at the North Plaza, 300 Athenaeum St., in Kendall Square. 

Corporate Pumpkin Challenge

Throw down a Challenge to other Kendall Square companies to carve the most awesome, scariest pumpkins ever! Put together a corporate pumpkin carving team!  Get in touch with the inner kid who loved to go trick-or-treating and wear Dracula fangs and join us on October 18. (Rain date on October 25th)

The Great Pumpkin Patch will be waiting for you on October 18 at 4:00 in the North Plaza. Bring your creative juices and get carving! There will be refreshments, music and lots of fun! Carving tools and pumpkin decorations will be supplied and volunteers will be available for carving assistance.  Candy optional!

Ready to Glow

All carved pumpkins should be in place by 6:00 p.m. for their candles. The Pumpkin Glow will begin to shine at 6:15 p.m. as we light up the pumpkins. The best corporate team will be announced by the Boys & Girls Club kids at 6:30 p.m. At 7:00 p.m., you can retrieve your pumpkin or award it to a Club kid for their Halloween weekend!

This event supports the Boys & Girls Club of Middlesex County, with Clubhouses in Cambridge, Somerville, Medford and Everett, serving children who need a safe place to grow and learn after school.

Learn more and register here: https://secureonlinegiving.com/events/site/index.asp?eventID=987

 

4th Annual 5K4Life Race

0
0

The fourth annual 5K4Life Race will be held on Sunday, November 4, 2012 with a 10:00 am race start.

Entry fee includes long sleeve t-shirt, finisher medal, and post-race festivities (award ceremony, food, and both non-alcoholic and alcoholic beverages). All proceeds benefit Prize4Life and bring us closer to a world without ALS.

 For registration and complete race information, please visit www.5K4Life.org.  

North Shore Technology Council Seminar: Combination Products: An Overview of Clinical Benefits, Regulatory Issues & Manufacturing Challenges

0
0

North Shore Technology Council First Friday Bioscience Seminar Series

Join scientists and executives from local biomedical companies for the North Shore Technology Council’s First Friday Bioscience seminar series, sponsored by the Biosciences Group Biomedical Technology Section. In this informal venue you will meet industry peers, learn about the science behind area biomedical companies, and hear how they tackle business challenges. You’ll also connect with other scientists and executives and become part of a community of business neighbors who are committed to accelerating the growth of their companies and the region biomedical business sector.

Combination Products: An Overview of Clinical Benefits, Regulatory Issues & Manufacturing Challenges

Speaker:

  • Michael Drues, Ph.D., President, Vascular Sciences

Medical products, no matter how well designed, can only do so much to address many of today’s clinical problems. In order to tackle the clinical problems of the future, medical devices will be used in combination with drugs and biologics (called combination products) to treat a wide range of diseases from heart attack and stroke to Alzheimer’s, diabetes and beyond. During this interactive workshop, participants will be exposed to examples of combination products on the market, under development and on the drawing board. The workshop concludes with a fascinating look at the future of medicine including nano-medical device technology, tissue engineering and more. 

Vascular Sciences is an education, training, and consulting company offering a full range of consulting services to medical device, pharmaceutical and biotechnology companies including: prototype design, product development, testing and evaluation, animal and clinical trials, business development, strategic planning, technology assessment and regulatory affairs.

Pizza, salad and soft-drinks will be served.

Cost: Thanks to our host Complya Consulting Group, members and affiliates are admitted at no charge and non-members pay $10.00.

Please register online at http://nstc.org/. For more information, email FirstFridayBiosci@nstc.org.

 

Host: Complya Consulting Group (Cambridge, MA, http://www.complya.com/) provides FDA compliance services for small to huge device and biotech/pharma companies. Complya’s services include writing SOPs, auditing, reviewing data, and preparing regulatory filings; our mission is to provide Regulatory Peace of Mind through strategic and tactical consulting services.

CT & BSDM: Using Quantitative Models as Tools to Improve Drug Development Strategy & Decision-Making

0
0

Small and mid-sized biopharmaceutical companies face a number of drug development challenges. Quantitative modeling and predictive simulations of drug attributes, disease processes, and trial designs helps integrate preclinical and clinical data into knowledge that can influence drug development, regulatory and therapeutic decisions. These models can be applied within the cross-disciplinary fields of translational science, and can facilitate the interaction between basic research and clinical medicine.

This seminar provides an introduction to the value of quantitative models to improve knowledge of a compound’s attributes early in development, and to achieve tangible benefits for a company’s clinical program:

  • Getting the dose right
  • Requiring fewer or smaller clinical trials
  • Improving interactions with regulatory authorities
  • Developing therapeutics with better benefit/risk profiles (e.g., versus competing treatments)
  • Attracting investor funding, performing due diligence or securing a development partner

The benefits of quantitative drug-disease-trial modeling and simulation have been well demonstrated by FDA and industry sponsors. These analyses have provided time and cost savings by requiring fewer or smaller clinical trials, enabled improved interactions with regulatory authorities by minimizing review cycles, and ultimately resulted in improved therapeutics with better benefit/risk profiles (1).

Panelists:

  • Joga Gobburu, PhD, FCP, MBA, Professor, Executive Director, Center for Translational Medicine, Schools of Pharmacy & Medicine, University of Maryland (formerly Director, Division of Pharmacometrics at FDA)
  • Varun Garg, PhD, Senior Director, Clinical Pharmacology at Vertex Pharmaceuticals
  • JF Marier, PhD, FCD, Vice President and Lead Scientist, Pharsight Consulting Services

 

________________

1.            Goldberger MJ, Singh N, Allerheiligan S, Gobburu JVS, Lalonde R, et al. ASCPT Task Force for Advancing Pharmacometrics and Integration into Drug Development. Clin. Pharmacol. Ther. 2010;88 2:158–161.

 

Volunteer: Build Your Leadership Skills AND Make a Difference

0
0

Volunteer: Build Your Leadership Skills AND Make a Difference
Learn how to get as much as you give.

Thursday, November 1, 2012 7:00pm-9:00pm
Location: Monadnock Room, Broad Institute
7 Cambridge Center, Cambridge, MA
Speakers: Dr. Joanne Kamens and current AWIS volunteers


Please join MASS-AWIS to learn about what volunteering can do for you and about volunteer opportunities within MASS-AWIS. The evening will include a presentation by Dr. Joanne Kamens, testimonials by current AWIS volunteers, and time for networking with the speakers and attendees.


Registration Free for All!
Please RSVP at http://www.surveymonkey.com/s/G5B8RPP as we need a headcount.


Speaker: Dr. Kamens obtained her BA in Biology from the University of Pennsylvania and her PhD in Genetics from Harvard University. She has worked for 20 years in both pharma and biotech drug discovery settings with oligonucleotide, small molecule, and biologic therapeutics. She is currently the Executive Director of Addgene, the non-profit plasmid repository. Dr. Kamens was the founding president of the Massachusetts AWIS chapter, was instrumental in starting the MASS-AWIS Mentoring Circle program and currently serves as Director at Large for the HBA (Healthcare Business Women’s Association) Mentoring Program.

For GPS users: 415 main Street, Cambridge, MA 02142
Broad Institute is very close to Kendall / MIT red line T station.

MASS-AWIS would like to thank The Broad Institute for hosting this event.

To learn more about MASS-AWIS and other upcoming AWIS events, please visit www.mass-awis.org
Join AWIS to save money on events and to support our mission.

WIB-Greater Boston: Changing Careers - Navigating Changes into and within Biotech

0
0

Join us on November 1, 2012 from 5:30 p.m to 7:30 p.m. EDT for an exciting panel discussion followed by a networking opportunity. Many women in biotech will change paths over the course of their careers. This might mean a move out of the lab or elsewhere into functions like operations, clinical, marketing, business development or legal. For those thinking about their future, this program will highlight how people engineer career changes
into or within biotech, how biotech careers evolve and how you can guide your career
path over the near and long term.

Join us for a panel discussion with Carol Greve-Phillips, Chief Business Officer, Pronota, Denise Aronson, President, Safety Partners and Lauren Celano, CEO, Propel Careers, about how they and others have achieved successful career changes. We’ll also include plenty of time for your questions, discussion and networking.


Cost for Reception  

Members: $25
Non-Members: $45 

Please use the following link to register:

https://netforum.avectra.com/eweb/DynamicPage.aspx?Site=WIB&WebCode=EventDetail&evt_key=852927ec-4ea9-44b2-bc45-509d6f9522d4

MassBio Pizza Lunch: Cambridge

0
0

Come meet the MassBio team on Wednesday, October 31st from Noon-2 PM and enjoy FREE PIZZA!

MassBio is the nation’s first and preeminent biotechnology trade association. We can help with everything that your biopharma company needs to succeed. Our mission is to create an environment that enables each member company to achieve its utmost potential. If you’d like to learn more about MassBio and enjoy free pizza join us in the lobby of One Kendall Square in Cambridge, MA.

For more information contact: Jon Allard, Manager of Business Development . 617-674-5100 or jon.allard@massbio.org


Driving Innovation in a Collaborative Biopharma Ecosystem (Webinar)

0
0

Webinar | Oct 30 2012 | 8:00am-9:00am PDT, 11:00am-12:00pm EDT, 15:00-16:00 GMT

http://www.wuxiapptec.com/pdfs/Driving%20Innovation%20Speaker%20Bios%20FINAL.pdf

New avenues to innovation, productivity and efficiency are vital in bringing new medicines for global, unmet medical need.  Open innovation, open access platforms, and partnership among industry, academic, non-profits, venture capital community and service providers are forming the foundation to a new collaborative biopharma ecosystem and creating novel paradigms of R&D. In this live webinar open to life science professionals globally, WuXi brings together key thought leaders and players to examine how this ecosystem may impact future of R&D, and how it may benefit patients.

Round-Table Discussions with:

Greg Verdine, Venture Partner of Third Rock Ventures, Erving Professor of Chemistry at Harvard University, Founder of Warp Drive Bio

Mike Varney, Senior Vice President of Small Molecule Research, Genentech

Joe Vacca, Senior Vice President, Early Success Sharing Partnerships, WuXi AppTec

Chris Chen, Senior Vice President and CTO, Biologics Services, WuXi AppTec

Moderated by Richard Soll, Senior Vice President of Integrated Services and Head of Corporate Alliances, WuXi AppTec

Registration: Complimentary and open to life science professionals globally. Click Here to Register.

https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&eventid=519131&sessionid=1&key=318D26E4180C5A471C9F2AE9D17DA4A4&sourcepage=register

 

Speaker Biographies

Mike Varney, Senior Vice President of Small Molecule Research, Genentech. Dr. Michael D. Varney received his B.S. in Chemistry in 1980 from UCLA, and his Ph.D. in synthetic organic chemistry from CalTech in 1985 under the direction of Professor Robert E. Ireland. He was an American Cancer Society postdoctoral fellow at Columbia University where he studied bioorganic chemistry under the direction of Ronald Breslow from 1985-1987. In 1987 he went to Agouron Pharmaceuticals Inc. as a medicinal chemist. In 1997 he was given responsibility for the Research organization as the Corporate Vice President, Head of Research. As part of the acquisition of Warner-Lambert by Pfizer, Mike became the Vice President of Drug Discovery Pfizer Global Research and Development, La Jolla. In 2005 Dr Varney moved to Genentech as the Vice President, Small Molecule Drug Discovery. Dr Varney is now the Senior Vice President, Research and Small Molecule Drug Discovery where he is responsible for all Small Molecule activities as well as the Research portfolio and budget. Dr Varney is also the Co-Chair of the Early Stage Portfolio Committee which is responsible for the management of all aspects of Genentech’s Development portfolio. Dr Varney’s research has focused on the use of combinatorial chemistry and protein structural information in the design of therapeutically relevant drugs in the fields of Viral Diseases, Diabetes, Obesity, Oncology, Ophthalmology, Immunology and Neurodegeneration. Outside of work, he likes swimming and biking with his wife and two children, playing his guitar and nurturing his palm tree collection.

Greg Verdine, Venture Partner of Third Rock Ventures, Erving Professor of Chemistry at Harvard University, Founder of Warp Drive Bio. Professor Gregory L. Verdine’s research interests lie in the emerging area of chemical biology. He and his co-workers study biologic processes underlying control of gene expression and preservation of genomic integrity. He has made major contributions to the understanding of DNA damage recognition and repair by base-excision DNA repair enzymes. He has also pioneered new and powerful approaches for the discovery of unconventional bioactive ligands for targets that have proven difficult to target with conventional drugs. Professor Verdine received his B.S. degree in 1982 from St. Joseph’s University and his Ph.D. in 1986 from Columbia University (under Koji Nakanishi and Maria Tomasz). Following an NIH postdoctoral fellowship with Chris Walsh at M.I.T. and Harvard Medical School, he joined the Harvard University Department of Chemistry in 1988. Verdine was promoted to Full Professor in 1994 and was also named Harvard College Professor in 2000. In 2002, he was named the Erving Professor of Chemistry, the longest-established endowed professorship at Harvard. Professor Verdine has received numerous honors, including the Arthur C. Cope Scholar Award, the Nucleic Acids Award of the Royal Society of Chemistry, the Cruikshank Award of the Gordon Research Conferences, the Nobel Laureate Signature Award of the American Chemical Society (with Anirban Banerjee), and the Fifth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research. He has founded numerous drug discovery companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Eleven Biotherapeutics, and Warp Drive Bio. He is a Venture Partner at Third Rock Ventures, at which he leads the initiative in next-generation therapeutic modalities.

Joe Vacca, Senior Vice President, Early Success Sharing Partnerships, WuXi AppTec. Dr. Vacca is Senior Vice President of Early Success Sharing Partnerships atWuXiAppTec. Most recently prior to WuXi, Dr. Vacca held two positions within the Merck Research Laboratories Chemistry organization as Vice President of Chemistry at the Kenilworth, New Jersey site and as the Global Head of Structural Chemistry until his retirement from Merck in Nov. 2011. Dr. Vacca has over 100 publications and patents and is the holder of many awards including a Merck Directors Award given by the Merck board of Directors (1998); PhRMA Discoverers Award (1999); Intellectual Property Owners "National Inventor of the Year Award" (1997); European Inventor of the Year (non-EU nation) (2007); ACS "Award for Creative Invention" (1999); and was named a Merck Research Laboratories Presidential Fellow in 2008. Dr. Vacca was inducted to the American Chemical Society Medicinal Chemistry Hall of Fame in 2012.

Dr. Chris Chen, Senior Vice President and Chief Technology Officer of Biologics, WuXiAppTec. Dr. Chris Chen is currently Senior Vice President and Chief Technology Officer for Biologics Service at Wuxi AppTec Co Ltd, leading biologics service business in China. He obtained his dual bachelor degrees of chemical engineering and automation at Tsinghua University, Beijing China and his Ph.D. in chemical engineering at the University of Delaware, US. He then gained valuable experience in process development, manufacturing, technology transfer, process validation, quality, and regulatory in the US, where his previous assignments include director and manager positions of bioprocess development, technical service, and pilot plant operations at Lilly and Merck. He later joined Shanghai Celgen Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar Enbrel, and obtained regulatory approval for the program in China. The biosimilar Enbrel was launched in China Sept 2011. In 2009, he co-founded Shanghai Kanda Biotechnology Co Ltd and served as Chief Executive Officer. In two years Kanda became a leading mab CRO/CMO provider in China, successfully completing two Chinese IND-enabling CMC projects on behalf of clients. He is proficient at mab development strategy, high titer cell culture development, large-scale mammalian cell culture, and regulatory and quality of mab manufacturing. Overall he has participated in developing 11 mab programs in US and another 10 in China. He chaired multiple conferences in biochemical engineering and mab development in US and China and is frequently invited to speak at multiple conferences.

Richard Soll, Senior Vice President of Integrated Services and Head of Corporate Alliances, WuXi AppTec. Dr. Richard M Soll is SVP, Integrated Services and Head of Corporate Alliances at WuXiAppTec, a Shanghai headquartered and New York Stock Exchange listed (NYSE: WX) premium provider of pharmaceutical R&D services across. In this capacity, Dr. Soll has advanced more than 30 programs across major target classes and therapeutic indications from hits into lead opitmization campaigns, giving rise to clinical candidates on behalf of WuXi customers in pharma and biotech. In addition, Dr. Soll heads Corporate Alliances Office at WuXi, oversees strategic partnering activities with our global partners in designing and executing creative collaboration models to maximize R&D productivity and shorten time to market. Previously, WuXi, Dr. Richard Soll was CSO and VP, R&D at TargeGen where he led innovative clinical-stage R&D programs for isoform-specific PI3K inhibitors as therapeutics for inflammation, respiratory disease and cancer, muti-targeted src/VEGF inhibitors as the first topical kinase inhibitors AMD, and highly selective JAK2 inhibitors for the treatment of myeloproliferative disorders, the latter leading to the acquisition of TargeGen by Sanofir. Dr. Soll founded the chemistry department 3-DP as VP, Chemistry. Dr. Soll spent 10 years at Wyeth Pharmaceuticals, and trained as a synthetic chemist at Dartmouth and Harvard. Dr. Soll’s drug discovery and development experiences has led to more than 7 drug candidates entering and advancing the clinic for infectious disease, cardiovascular disease, cancer, and ocular indications up to pivotal trials. Dr. Soll’s patent and publication record in peer reviewed journals has produced more than 100 patents and papers. Dr. Soll has been an SAB member to biotechs and advisor to entrepreneurs.

 

Combination Products: An Overview of Clinical Benefits, Regulatory Issues, & Manufacturing Challenges

0
0

North Shore Technology Council First Friday Bioscience Seminar Series

Join scientists and executives from local biomedical companies for the North Shore Technology Council’s First Friday Bioscience seminar series, sponsored by the Biosciences Group Biomedical Technology Section. In this informal venue you will meet industry peers, learn about the science behind area biomedical companies, and hear how they tackle business challenges. You’ll also connect with other scientists and executives and become part of a community of business neighbors who are committed to accelerating the growth of their companies and the region biomedical business sector.

Combination Products: An Overview of Clinical Benefits, Regulatory Issues & Manufacturing Challenges

Speaker:

  • Michael Drues, Ph.D., President, Vascular Sciences

Medical products, no matter how well designed, can only do so much to address many of today’s clinical problems. In order to tackle the clinical problems of the future, medical devices will be used in combination with drugs and biologics (called combination products) to treat a wide range of diseases from heart attack and stroke to Alzheimer’s, diabetes and beyond. During this interactive workshop, participants will be exposed to examples of combination products on the market, under development and on the drawing board. The workshop concludes with a fascinating look at the future of medicine including nano-medical device technology, tissue engineering and more. 

Vascular Sciences is an education, training, and consulting company offering a full range of consulting services to medical device, pharmaceutical and biotechnology companies including: prototype design, product development, testing and evaluation, animal and clinical trials, business development, strategic planning, technology assessment and regulatory affairs.

Pizza, salad and soft-drinks will be served.

Cost: Thanks to our host Complya Consulting Group, members and affiliates are admitted at no charge and non-members pay $10.00.

Please register online at http://nstc.org/. For more information, email FirstFridayBiosci@nstc.org.

OnLine Registration Closes on November 1, the night before the event at 5 p.m. - REGISTER HERE

 

Host: Complya Consulting Group (Cambridge, MA, http://www.complya.com/) provides FDA compliance services for small to huge device and biotech/pharma companies. Complya’s services include writing SOPs, auditing, reviewing data, and preparing regulatory filings; our mission is to provide Regulatory Peace of Mind through strategic and tactical consulting services.

SEF: Getting Senior Management Support for Environmental Health & Safety (EH&S)

0
0

You’re walking down the beach and you stub your toe.  When you bend over to see what it was, you find a brass lantern. As you rub it, a genie comes out and offers you (the EH&S Manager) three wishes. 

Your first wish is … “I wish our senior management cared more about EHS.”

Your second … “I wish our senior management was more involved in the EH&S program.”

Your third … “I wish our organization would spend more on its EH&S program.”

If you would like to have these wishes granted, don’t miss the presentation by Dr. James Kaufman, President and CEO of the Laboratory Safety Institute. Jim is going to present some of the ideas that he’s shared with company and university senior managers and EH&S directors on leadership in safety and how to convince others that EH&S is important.

For over 30 years, Dr. Kaufman has made thinking about health and safety an energizing and enjoyable experience.  Dr. Kaufman is a former, ten-year member of the American Chemical Society's (ACS) Council Committee on Chemical Safety and is past-chairman of the 2,500-member ACS Division of Chemical Health and Safety.  Most recently, Dr. Kaufman was appointed chair of the Safety In Science Education Committee of the International Council of Associations for Science Education.

Don't miss this special opportunity and feel free to invite senior management to attend and provide their perspective. 

Phacilitate Leaders’ Forum 2012

0
0

Phacilitate Leaders' Forum is made up of 3 conferences running in parallel: 

  • CNS Leaders Forum
  • Oncology Leaders Forum
  • R&D Leaders Forum 

Discovery the latest developments in R&D, oncology and CNS strategies, analyzing the evolving marketplaces, how to attract funding, and how you must adapt to align with ongoing macro trends and developments at the same time as networking with numerous senior R&D decision makers.

The 3 forums run in parallel, with attendees having unlimited access to all 3 conferences.

MassBio members get a 10% discount off the registration fee!

For more information including the full agendas and speakers lists, visit the event websites: 

www.oncology-leaders.com

www.cns-leaders.com

www.rd-leaders.com

Or email team@phacilitate.co.uk or call us on +44 (0)20 7384 8046.

 

http://www.phacilitate.co.uk/event.php?eid=26&pid=538

New England Israel Business Council Life Science Summit

0
0

 

SAVE THE DATE! November 5-6, 2012 Life Science Summit 

The two-day Summit at the Westin Hotel in Waltham (MA) will cover key topics affecting today's delivery of healthcare and presenting promising Israeli life science companies addressing tomorrow's challenges. Keynote address at the Gala Dinner on November 5th by Dr. Gary Gottlieb, President and CEO of Partners HealthCare. Online registration is now available! Take advantage of early bird discounted rates and special NEIBC member only rates.

For further details about the summit and sponsorship opportunities please go to www.lss2012.com or contact Debbie Kurinsky at debbie@neibc.org

Link to registration: http://www.lss2012.com/register.shtml.

 

4th Annual 5K4Life Race

0
0

The fourth annual 5K4Life Race will be held on Sunday, November 4, 2012 with a 10:00 am race start.

Entry fee includes long sleeve t-shirt, finisher medal, and post-race festivities (award ceremony, food, and both non-alcoholic and alcoholic beverages). All proceeds benefit Prize4Life and bring us closer to a world without ALS.

 For registration and complete race information, please visit www.5K4Life.org.  

iGEM, Synthetic Biology Competition Finals and Awards Jamboree

0
0

The International Genetically Engineered Machines (iGEM) Competition is the preeminent Synthetic Biology competition for college and high school students around world. This year we have nearly 3000 students participating, comprising over 200 teams from many corners of the globe.

A total of 62 teams will participate in the Final Jamboree after having advanced from the five regional semi-final Jamborees: Hong Kong (Asia), Amsterdam (Europe), Bogota (Latin America), Palo Alto (Americas West) and Pittsburgh (Americas East.)

Join us to see what the next generations of life scientists are developing. Not only is iGEM a premier STEM educational activity for students, it also provides a peek into the work of academic labs, researchers and entrepreneurs in the rapidly emerging field of Synthetic Biology. In addition to the technical collegiate competition hosted Saturday through Monday, November 3-5th, this is the first year we will be hosting the iGEM Entrepreneurship division, taking place on Sunday November 4th, 2012.

Special non-profit and industry registration rates are available. Please visit http://2012.igem.org/World_Championship_Jamboree for more information. For information about the entrepreneurship division please contact Jose J. Pacheco directly at jose@igem.org. 


World ADC 3rd Annual Meeting:

0
0

World leaders in antibody-drug conjugate field are descending on San Francisco.

Join them now to develop the optimal ADC. Faster. 

Download the brochure to see the full program.

There’s no other meeting where you can find every major player, all under one roof. Whether you want to learn, network, identify new partnerships or even just size the field up, this meeting will ensure you gain complete perspective on the ADC field and provide comprehensive insights into ADC development, from antibody selection and linker-payload design to manufacturing and commercialization.

Learn from more than 50 leading ADC scientists from 33 individual companies within pharma, biotech, regulatory agencies, platform technology providers, CSO companies, academia and clinical oncology, who will provide you with the information you need to achieve your ADC goals.

See the extended speaker line-up.

For more information & to register, visit: http://adc-summit.com/

MassBio Coffee Break: Beverly

0
0
  • Want to get the best rates on everything from lab consumables to office supplies?
  • Looking to make new connections?
  • Want to learn more about available funding for your start-up?
  • Need help navigating the difficult road of entrepreneurship?
  • Looking to make a deal?

If you answered YES to any of these questions, MassBio can help! Come meet the MassBio team on Friday, November 9 from 8:30-10:30am and enjoy a FREE continental breakfast!
 
MassBio is the nation’s first and preeminent biotechnology trade association. We can help with everything that your biopharma company needs to succeed. Our mission is to create an environment that enables each member company to achieve its utmost potential.
 
If you’d like to learn more about  MassBio, and enjoy a free continental breakfast, join us in the Community Conference Room, Suite 221-E.

Contact jon.allard@massbio.org for more information.

Spinal Cord Workshop

0
0

HOW CLOSE IS A CURE?

The last few years have brought remarkable advances in stem cell research. But how are these laboratory advances translated into human cures? Are there unanswered scientific questions? Are there unanswered clinical approach problems? Are there unanswered healthcare regulatory issues?

During this groundbreaking, one-day event, leaders in science and surgery will meet to share their work and discuss the state of the field.

150 Second Street Open House

0
0

The Kendall Square Association & Skanska invite you to welcome 150 Second to the neighborhood!

Please join us for an Open House with live music and complimentary food and drink to celebrate the newly finished facility. All attendees will be entered into a raffle with items from local Kendall Square businesses.

Click here to register.

Music by: Ed Dondero's own Boston Blues Revue

Parking: On-site parking at 150 Second Street (entrance on Bent Street)

null

 

 

http://events.r20.constantcontact.com/register/event?llr=778w98kab&oeidk=a07e6hwwtx3a9cf1ef3

 

IS YOUR FUTURE IN BIOTECH?

0
0

Boston is one of the world’s preeminent biomedical centers. Today’s rapid pace of innovation and high demand for qualified professionals present a broad range of opportunities for those with the right training. That’s why it is so critical to learn from the best in the field.

Boston University’s Metropolitan College and School of Medicine collaborate in offering the Bachelor of Science in Biomedical Laboratory & Clinical Sciences—an outstanding academic program that will prepare you for a rewarding career in biotech.

• Study at a top university medical campus, in a biotech hub.
• Practice skills sought by innovative companies and start-ups.
• Benefit from flexible part- and full-time options to suit your schedule.

Students accepted to the degree program may qualify for BU’s
new SCILS Scholarship. Please inquire at the Information Session or email biomed@bu.edu.

For those who already have a foundation in biology, chemistry, and math and who wish to earn a professional credential, BU’s Metropolitan College also offers certificates in Biotechnology
and in Clinical Research.

About BU’s Metropolitan College
MET is one of Boston University’s 16 degree-granting schools and colleges. Among the highest-ranked academic institutions in the world, MET offers a truly superior educational experience.

To register, visit bu.edu/met/info.

Viewing all 2057 articles
Browse latest View live




Latest Images